Thus, the ADVIA Centaur Assay Method Manual encourages individual laboratories to establish their own reference ranges, but Carmel et al. fail to provide any information that they have done so. They apparently have chosen as their medical decision point the 2.5th percentile of the normal population from the ADVIA Centaur VB12 Assay Method Manual. This decision point optimizes the clinical specificity of the assay at the expense of clinical sensitivity, which at least partially explains why Carmel et al. might be missing cobalamin-deficient patients.
We believe the best way to compare clinical performance of tests is through ROC curve analysis (4 ) . Such a comparison automatically compensates for systematic analytical biases among the methods and the prevalence of disease in the study population. Such an analysis requires a symmetric study design and that each test be treated equally. A study design that uses the RIDA (even in combination with other clinical and laboratory information) to identify cobalamin-deficient patients is biased against any other cobalamin assay. The study by Carmel et al. also falls short of identifying clinical false negatives with the RIDA.
Furthermore, we advise extreme caution before drawing conclusions from samples stored at Ϫ20°C for up to 10 years (Dr. Carmel has told us that this is the approximate storage interval) when an authoritative source (1 ) indicates that samples stored at Ϫ20°C are stable for 8 weeks.
Finally, 17 banked diagnosed cobalamin-deficient samples used to determine the deficient range of the ACS:180 assay in 1996 and stored since then at Ϫ80°C were run concurrently on the ACS:180, ADVIA Centaur, and where possible, the Bio-Rad RIA. Cutoffs were taken from the manufacturers' package inserts (211 ng/L ϭ 156 pmol/L for ACS:180 and ADVIA Centaur; 200 ng/L ϭ 148 pmol/L for Bio-Rad RIA). The results in Table 1 show that the recent determinations compare favorably with historical data and show similar diagnostic classifications across methods. An additional 49 low-cobalamin samples (range, 144 -389 ng/L; mean, 222 ng/L) were obtained and tested on the ADVIA Centaur and Bio-Rad RIA, and clinical concordance between the two methods was 92%.
On the basis of the data presented in the two studies above, we conclude that the ADVIA Centaur VB12 assay provides accurate cobalamin values consistent with the clinical interpretation.
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Long-Term Stability of Nelfinavir Mesylate in Human Plasma
To the Editor: Nelfinavir mesylate (NFV) is an HIV protease inhibitor approved for the treatment of HIV infection. Since its introduction, NFV has become a common component of standard highly active antiretroviral regimens. Although the drug has been available since 1997, the pharmacokinetic and pharmacodynamic properties of NFV and its active hydroxy-t-butylamide (M8) metabolite have not been well characterized. We recently completed investigations into the stability of NFV and M8 in plasma stored at Ϫ20 and Ϫ70°C for up to 19 months. We observed significant degradation of both compounds in heparinized plasma samples stored at Ϫ20°C. These results may have implications for those involved with the collection and analysis of NFV and M8 pharmacokinetic data.
To facilitate our investigations, we prepared NFV and M8 calibrators in drug-free heparinized human plasma at three concentrations (125, 1500, and 4000 g/L) in 10-mL batches. These concentrations cover the expected systemic exposure observed clinically in patients receiving Food and Drug Administration-approved NFV dosing regimens. Samples were prepared in October 1998 as calibrators of known concentrations and were used for validation of the NFV/M8 assay. The 10-mL aliquots of each concentration were stored at Ϫ20°C and assayed in triplicate after storage at 9, 14, and 19 months. As time progressed and changes in chromatographic results raised suspicions of instability, a second set of calibrators was prepared in June 1999. The new set of calibrators (5 mL per concentration) was stored at both Ϫ20 and Ϫ70°C. These aliquots were assayed in triplicate after 6 and 11 months of storage, using a validated HPLC-ultraviolet detection method developed specifically for quantification of NFV and M8 in heparinized plasma at the University of Alabama at Birmingham.
Analytical stability testing during assay validation is typical, and data on NFV stability have been reported (1) (2) (3) . Few reports, however, have examined storage stability over time after samples have been harvested. Our data confirm a previous report of NFV stability in heparinized human plasma at Ϫ20°C for 142 days (1 ) and introduces M8 stability information. After 6 months of storage at Ϫ20°C, our results showed Յ10% degradation for both NFV and M8. This is generally considered not significant because it falls within allowable experimental error. At 9 months, storage at Ϫ20°C demonstrated significant losses of 33-36%. By 19 months, losses as high as 73-83% were evident (Table 1) . Conversely, calibrators stored at Ϫ70°C showed no loss at 6 and 11 months.
Chromatographic evidence of degradation is apparent by the appearance of two unknown peaks in calibrators stored at Ϫ20°C. The unknown peaks elute just before M8. The relative retention times are 0.8 and 0.9, with baseline to near-baseline resolution, and they do not interfere with the quantification of either NFV or M8. The unknown peaks appear to be proportional to the concentration of NFV and M8 because they are larger in higher concentration calibrators. In addition, they increase in intensity relative to NFV and M8 as the length of storage increases. The unknown peaks have not been identified but are presumed to be degradation products of NFV and M8. Samples prepared from the same batch and stored for the same period of time show similar cumulative peak height totals for the nondegraded samples (two peaks; storage at Ϫ70°C) vs the degraded samples (four peaks; storage Ϫ20°C). This conservation of mass supports the assumption of degradation.
Understanding the stability of a drug after sample collection is critical to ensuring proper analytical and subsequent pharmacokinetic results. It is unclear why this information was not apparent earlier in the devel-opment process for NFV. Clinical and analytical laboratories are cautioned to make certain that heparinized plasma samples containing NFV are stored at Ϫ70°C or lower if storage is anticipated to exceed 6 months.
Discrimination of the Nature of Doping with 19-Norsteroids through Hair Analysis
To the Editor: Nandrolone (19-nortestosterone or 17␤-hydroxy-19-nor-4-androsten-3one) has been one of the most abused anabolic steroids, and doping practices are increasing, as revealed by numerous positive cases during recent years. Athletes use nandrolone because it has been claimed to increase lean body mass, strength, and aggressiveness, and shorten the recovery time between workouts. Ϫ0.6 (14) ND 10 (3) ND ND a Reported as percentage of average loss based on expected concentrations (SD in parentheses). b ND, not done.
